Table 3.
|
|
Age group (y) |
Resistant isolates according to CLSI criteria† |
|||
---|---|---|---|---|---|---|
Serotype |
Confirmed IPD |
<2 |
2-4 |
Penicillin | Erytromicin | Tetracycline |
(n = 13) | (n = 7) | (n = 6) | ||||
19A |
3 (23.1) [2] |
2 (28.6) [1] |
1 (16.7) [1] |
--- |
1 (7.7) |
--- |
1 |
2 (15.4) [2] |
--- |
2 (33.3) [1] |
--- |
--- |
--- |
7F |
2 (15.4) |
1 (14.3) |
1 (16.7) |
--- |
--- |
--- |
19F |
2 (15.4) |
--- |
2 (33.3) |
--- |
2 (15.4) |
2 (15.4) |
14 |
1 (7.7) |
1 (14.3) |
--- |
--- |
1 (7.7) |
--- |
23F |
1 (7.7) |
1 (14.3) |
--- |
--- |
--- |
--- |
12B |
1 (7.7) |
1 (14.3) |
--- |
--- |
--- |
--- |
15C |
1 (7.7) |
1 (14.3) |
--- |
1 (7.7) |
--- |
1 (7.7) |
Total | 13 (100) | 7 (100) | 6 (100) | 1 (7.7) | 4 (30.8) | 3 (23.1) |
Data are number (column percentage) of cases. Number of cases having received any pneumococcal vaccine previously within square brackets
†Clinical and Laboratory Standards Institute [26.] The overall coverage rate, estimated on typified IPD cases, was 30.8% for PCV7 and 84.6% for PCV13. The coverage rate of PCV7 and PCV13 was, respectively, 28.6% and 71.4% in infants, and 33.3% and 100% in children aged 2–4 years.